Menopause and Weight Gain: Why It Happens and What Helps
Menopause is defined as the point at which a woman has not had a menstrual period for 12 consecutive months. The transition leading up to it, perimenopause, can begin years earlier and is when most of the hormonal changes take place. Weight gain and changes in body composition often begin during perimenopause and continue into the postmenopausal years.
According to the Australasian Menopause Society, the average Australian woman gains between 0.5 and 2.5 kilograms per year during the menopausal transition. While some of this is attributable to normal ageing, the pattern and distribution of weight gain during menopause is distinct from what occurs at other life stages. Specifically, there is a shift toward increased abdominal or visceral fat, even in women whose overall weight does not change dramatically.
Research published in the Journal of Clinical Endocrinology & Metabolism has shown that this redistribution of fat is closely linked to declining oestrogen levels, rather than being solely the result of lifestyle factors. Women who undergo surgical menopause (removal of the ovaries) often experience a more rapid version of the same pattern, which further supports the hormonal connection.
It is important to recognise that weight gain during menopause is not inevitable for every individual, and the degree of change varies widely. But for the majority of women going through this transition, some degree of body composition change is a normal biological response to shifting hormones. For those earlier in the transition, our guide to perimenopause symptoms and what to expect covers the broader picture of hormonal change, including how body composition starts shifting before periods stop entirely.
Oestrogen is the hormone most closely associated with female reproductive health, but its influence extends well beyond the reproductive system. It plays a significant role in regulating where the body stores fat, how efficiently it burns energy, and how much lean muscle mass is maintained.
Before menopause, oestrogen promotes what is sometimes called a "gynaecoid" fat distribution pattern, where fat is stored predominantly in the hips, thighs, and buttocks. This pattern is associated with a lower risk of cardiovascular disease and metabolic syndrome compared to abdominal fat storage. As oestrogen levels decline during the menopausal transition, the body shifts toward an "android" pattern, storing more fat around the abdomen and internal organs.
This is not a cosmetic distinction. Visceral fat (fat stored around the organs in the abdominal cavity) is metabolically active and associated with increased risks of type 2 diabetes, cardiovascular disease, and certain cancers. A review published by the National Health and Medical Research Council (NHMRC) notes that waist circumference is an independent risk factor for cardiometabolic disease in postmenopausal women, regardless of overall body weight. The NHMRC identifies a waist circumference above 80 cm in women as indicating increased health risk, and above 88 cm as indicating substantially increased risk.
Oestrogen also influences insulin sensitivity. As oestrogen declines, cells become less responsive to insulin, which can lead to higher circulating blood sugar levels and increased fat storage, particularly in the abdominal area. This creates a metabolic environment that favours weight gain even when caloric intake has not changed.
Additionally, oestrogen supports the maintenance of lean muscle mass. With declining oestrogen levels, there is a gradual loss of skeletal muscle (a process known as sarcopenia), which reduces basal metabolic rate. In practical terms, the body burns fewer calories at rest than it did a decade earlier, making it easier to gain weight and harder to lose it.
The metabolic shifts that accompany menopause are multifaceted and go beyond a simple "slower metabolism" narrative. Understanding what is actually changing at a physiological level helps explain why the experience can be so different from weight management at other stages of life.
Resting metabolic rate declines. Research published in the International Journal of Obesity estimates that resting metabolic rate decreases by approximately 100 to 200 calories per day during the menopausal transition, driven primarily by the loss of lean muscle mass. Over a year, this can translate to meaningful weight gain even without any change in eating habits.
Insulin resistance increases. The decline in oestrogen impairs insulin signalling, making it harder for the body to process carbohydrates efficiently. A study in Diabetes Care found that postmenopausal women had significantly higher fasting insulin levels and greater insulin resistance compared to premenopausal women of similar age and body composition. This shift promotes fat storage and can make blood sugar regulation more challenging.
Cortisol and stress responses shift. The menopausal transition is associated with changes in the hypothalamic-pituitary-adrenal (HPA) axis, which governs the stress response. Higher cortisol levels, particularly when sustained, promote visceral fat accumulation. Sleep disruption, which is common during menopause and often driven by night sweats and hormonal changes, further elevates cortisol and disrupts the appetite-regulating hormones ghrelin and leptin.
Gut microbiome changes. Emerging research, including studies published in Menopause: The Journal of the North American Menopause Society, suggests that oestrogen decline is associated with changes in gut microbiome composition. These changes may influence energy extraction from food, inflammation, and fat storage, though this area of research is still developing.
Thyroid function deserves consideration. While menopause itself does not cause thyroid disease, the incidence of hypothyroidism increases with age and can compound the metabolic changes of menopause. Healthdirect Australia recommends that unexplained weight gain, fatigue, and other overlapping symptoms be investigated with thyroid function testing, particularly if they are not clearly attributable to the menopausal transition alone.
The cumulative effect of these changes is a metabolic environment that is genuinely different from what existed before menopause. Strategies that worked for weight management at 30 or 35 may not be effective at 50. This is not because of a lack of effort. It is because the underlying biology has changed.
While hormonal changes create real metabolic challenges, lifestyle interventions remain the foundation of weight management during and after menopause. The evidence supports several specific approaches, though individual results will vary depending on starting point, health history, and other factors.
Resistance Training and Muscle Preservation
Of all lifestyle interventions, resistance training has perhaps the strongest evidence base for managing body composition during menopause. A systematic review published in Osteoporosis International found that progressive resistance training improved lean muscle mass, reduced visceral fat, and improved insulin sensitivity in postmenopausal women.
Resistance training addresses one of the core mechanisms of menopausal weight gain: the loss of muscle mass that drives down resting metabolic rate. It also supports bone density, which is another area of concern after menopause. The RACGP recommends that postmenopausal women engage in muscle-strengthening activities at least two days per week.
Resistance training does not need to be complicated. Bodyweight exercises, resistance bands, dumbbells, or gym-based programmes can all be effective. The key is consistency and progressive overload (gradually increasing the challenge over time).
Aerobic Exercise
Regular aerobic activity (walking, swimming, cycling) supports cardiovascular health and contributes to overall energy expenditure. The Australian Government's Physical Activity Guidelines recommend 150 to 300 minutes of moderate-intensity aerobic activity per week for adults. Research published in Menopause found that women who maintained regular aerobic exercise during the menopausal transition gained less visceral fat than those who were inactive.
The combination of resistance training and aerobic exercise appears to be more effective than either alone. A meta-analysis published in the British Journal of Sports Medicine concluded that combined exercise programmes produced the greatest improvements in body composition, metabolic markers, and cardiovascular fitness in postmenopausal women.
Dietary Quality Over Restriction
Severe calorie restriction is generally counterproductive during menopause. It can accelerate muscle loss, reduce metabolic rate further, and is difficult to sustain. Instead, the evidence supports focusing on dietary quality rather than caloric deprivation.
Adequate protein intake. Protein is essential for maintaining muscle mass during menopause. The NHMRC recommends that women over 50 aim for approximately 0.75 grams of protein per kilogram of body weight per day, with some researchers suggesting that 1.0 to 1.2 g/kg may be more appropriate for women engaged in regular resistance training.
Mediterranean-style eating patterns. A large body of evidence, including research published in the American Journal of Clinical Nutrition, supports Mediterranean-style diets (rich in vegetables, fruits, whole grains, legumes, fish, and olive oil) for cardiovascular health and weight management. These diets have been specifically studied in postmenopausal populations and associated with reduced visceral fat and improved metabolic markers.
Minimising ultra-processed foods. Research suggests that reducing intake of ultra-processed foods and refined carbohydrates can improve insulin sensitivity, which is particularly relevant given the insulin resistance that accompanies menopause.
Sleep and Stress Management
Given the relationship between sleep disruption, cortisol, and weight gain, prioritising sleep hygiene is a practical component of any weight management approach during menopause. The Australasian Menopause Society notes that addressing the underlying causes of sleep disruption (such as treating night sweats with appropriate medical interventions) can have downstream benefits for weight management and overall wellbeing.
Stress management strategies, including regular physical activity, mindfulness practices, and where appropriate, professional psychological support, can help modulate cortisol levels. While these approaches alone are unlikely to produce significant changes in weight, they support the overall metabolic environment in which other interventions can be more effective.
For some individuals, lifestyle modifications alone may not be sufficient to manage menopausal weight gain, particularly when metabolic changes are significant or when symptoms are compounding. In these cases, medical treatments may be considered as part of a comprehensive approach. All medications discussed here are prescription-only and require a consultation with a registered medical practitioner.
Menopausal Hormone Therapy (MHT)
MHT (previously called HRT) is the most effective treatment for vasomotor symptoms such as hot flushes and night sweats, and there is evidence that it may also have beneficial effects on body composition. A review published in the Journal of Clinical Endocrinology & Metabolism found that MHT was associated with reduced visceral fat accumulation in postmenopausal women, though it did not necessarily reduce overall body weight.
The mechanism appears to be related to oestrogen's role in fat distribution and insulin sensitivity. By partially restoring oestrogen levels, MHT may help counteract the shift toward abdominal fat storage that occurs after menopause. The Australasian Menopause Society notes that for women within 10 years of menopause onset or under 60, the benefits of MHT generally outweigh the risks for most individuals.
MHT is not prescribed primarily for weight management, and it should not be positioned as a weight loss treatment. However, for women who are already considering MHT for symptom management, the potential body composition benefits are a relevant consideration to discuss with a GP. The type, dose, and delivery method of MHT should be tailored to each patient's circumstances, and treatment requires ongoing medical review.
For a detailed discussion of MHT types, risks, and benefits, see our guide: HRT in Australia: Is Hormone Replacement Therapy Right for You?
GLP-1 Receptor Agonists
GLP-1 receptor agonists are a class of medications that have received significant attention for weight management. Originally developed for type 2 diabetes, specific formulations have been approved by the Therapeutic Goods Administration (TGA) for weight management in adults who meet clinical criteria (generally a BMI of 30 or above, or 27 or above with weight-related comorbidities).
These medications work by mimicking a natural gut hormone that regulates appetite, slows gastric emptying, and improves blood sugar control. Clinical trials published in The New England Journal of Medicine have demonstrated meaningful reductions in body weight when GLP-1 medications are used alongside lifestyle modifications.
For postmenopausal women, GLP-1 medications may be particularly relevant because they address several of the metabolic challenges specific to this life stage, including insulin resistance and increased appetite signalling. However, they are prescription medications with specific eligibility criteria, potential side effects (including nausea, particularly during the initial titration phase), and they require ongoing medical supervision.
GLP-1 medications are not appropriate for everyone, and they are not a substitute for lifestyle interventions. No medication guarantees a specific amount of weight loss, and individual responses vary. Eligibility is determined through a clinical consultation, and treatment involves regular follow-up appointments to monitor response and adjust the approach as needed. A GP can assess whether this class of medication may be suitable based on individual circumstances.
For a comprehensive overview of GLP-1 medications in Australia, see our guide: GLP-1 Weight Loss Medications in Australia
Other Considerations
Some women may benefit from reviewing medications they are already taking that could contribute to weight gain, such as certain antidepressants, corticosteroids, or hormonal contraceptives. Thyroid function should also be assessed, as hypothyroidism becomes more common in midlife and can mimic or compound menopause-related metabolic changes. These are all conversations best had with a GP who can review the full clinical picture.
Weight changes during menopause?
Conversations about menopause and weight deserve more than a rushed appointment. They require a clinician who understands the hormonal context, who can review a full health history, and who has time to discuss the options that are appropriate for each individual situation.
At Abby Health, consultations are available seven days a week, 365 days a year, with a care network of over 300 clinicians. Appointments may be bulk billed for eligible patients with a valid Medicare card. Whether it is a first conversation about what might be contributing to weight changes or a follow-up to adjust a treatment plan, the clinical standard is the same.
When a consultation is booked, the GP has access to a patient's health history through Abby AI, our clinical decision-support tool. Abby AI surfaces relevant patient history, symptoms, and risk signals so that clinicians start each appointment already informed. It never diagnoses or prescribes. It simply ensures the doctor has the full picture before the conversation begins, which means the appointment time is spent on what matters rather than repeating information from scratch.
One of the things that matters most for menopause care is continuity. Weight management during menopause is rarely a single-appointment conversation. It involves understanding a patient's full health history, monitoring how lifestyle and medical interventions are working, and making adjustments over time. Abby Health's 71% rebook rate means that three in four patients see the same doctor again, which is the kind of continuity that supports better outcomes.
If a GP determines that medication is appropriate, whether that is MHT, a GLP-1 receptor agonist, or another treatment, prescriptions can be issued during the consultation and sent directly to a preferred pharmacy. There is no separate step or additional appointment required to get started.
For women who are also experiencing other perimenopausal or menopausal symptoms alongside weight changes, a single consultation can address multiple concerns. For more information on the broader menopausal transition, see our guide: Perimenopause: Symptoms, What to Expect, and When to See a Doctor
Booking a consultation is straightforward. You can start at abbyhealth.com.au.
Is weight gain during menopause inevitable? Not necessarily. While the majority of women experience some degree of body composition change during the menopausal transition, the extent varies widely. Factors including genetics, baseline fitness, dietary patterns, and whether symptoms like sleep disruption are being managed all influence outcomes. Evidence-based lifestyle strategies and, where appropriate, medical support can help manage weight during this transition. Individual results vary.
Does menopause slow metabolism? Yes, though not in the simplistic way it is often described. Resting metabolic rate declines during menopause, primarily because of the loss of lean muscle mass driven by declining oestrogen. Research estimates this decline at approximately 100 to 200 calories per day. Resistance training is one of the most effective ways to counteract this change by preserving and building muscle.
Can MHT (hormone therapy) help with menopausal weight gain? MHT is not prescribed specifically for weight loss. However, research suggests it may help reduce the accumulation of visceral (abdominal) fat that accompanies menopause. The Australasian Menopause Society notes that the body composition benefits of MHT are an additional consideration for women who are already candidates for hormone therapy based on their symptoms. Whether MHT is appropriate depends on an individual risk-benefit discussion with a GP.
Are GLP-1 medications suitable for menopausal weight gain? GLP-1 receptor agonists may be considered for individuals who meet specific clinical criteria for weight management. They are prescription medications that require a thorough consultation to assess eligibility, and they are used alongside lifestyle modifications, not as a standalone solution. Side effects, contraindications, and long-term management should all be discussed with a GP before starting treatment.
What type of exercise is best for managing weight during menopause? The evidence most strongly supports a combination of resistance training and aerobic exercise. Resistance training is particularly important during menopause because it helps preserve lean muscle mass, which supports metabolic rate and insulin sensitivity. The RACGP recommends muscle-strengthening activities at least two days per week alongside 150 to 300 minutes of moderate-intensity aerobic activity.
Editorial Standards
Notice something that doesn’t look right? Let us know at support@abbyhealth.app
-
Australasian Menopause Society. (2024). Information Sheet: Weight and Menopause. Retrieved from https://www.menopause.org.au
-
Healthdirect Australia. (2024). Menopause and weight gain. Australian Government Department of Health. Retrieved from https://www.healthdirect.gov.au
-
Royal Australian College of General Practitioners (RACGP). (2023). Guidelines for preventive activities in general practice (9th edition). Retrieved from https://www.racgp.org.au
-
National Health and Medical Research Council (NHMRC). (2013). Australian Dietary Guidelines. Retrieved from https://www.nhmrc.gov.au
-
Lovejoy, J.C. et al. (2008). Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity, 32(6), 949-958. doi:10.1038/ijo.2008.25
-
Greendale, G.A. et al. (2019). Changes in body composition and weight during the menopause transition. JCI Insight, 4(5), e124865. doi:10.1172/jci.insight.124865
-
Salpeter, S.R. et al. (2006). Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism, 8(5), 538-554. doi:10.1111/j.1463-1326.2005.00545.x
-
Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989-1002. doi:10.1056/NEJMoa2032183
-
Asikainen, T.M. et al. (2004). Exercise for health for early postmenopausal women: a systematic review of randomised controlled trials. Sports Medicine, 34(11), 753-778. doi:10.2165/00007256-200434110-00004
-
Leeners, B. et al. (2017). Ovarian hormones and obesity. Human Reproduction Update, 23(3), 300-321. doi:10.1093/humupd/dmw045
Editorial Standards: This article was written by Charlie Veitch and medically reviewed by Dr Ramu Nachiappan, FRACGP, who brings 35 years of general practice experience, including remote and rural medicine. Abby Health is committed to producing accurate, evidence-based health content sourced from peer-reviewed research and recognised Australian medical authorities. All clinical information is reviewed before publication to ensure it meets current best-practice standards.




%20Medium.jpeg)
.avif)





